• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lite Strategy Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    12/5/25 4:00:24 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LITS alert in real time by email
    8-K
    0001262104false00012621042025-12-022025-12-02

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 02, 2025

     

     

    Lite Strategy, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41827

    51-0407811

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    9920 Pacific Heights Blvd.,

    Suite 150

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 858 369-7100

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.00000002 par value

     

    LITS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 4.01 Changes in Registrant’s Certifying Accountant.

    The Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Lite Strategy, Inc. (the “Company”) undertook a selection process to determine the Company’s independent registered public accounting firm for the current fiscal year ending June 30, 2026. On December 2, 2025, the Committee approved the engagement of CBIZ CPAs P.C. (“CBIZ CPAs”) as its independent registered public accounting firm for the fiscal year ending June 30, 2026. At the same time, the Committee dismissed Deloitte & Touche LLP (“Deloitte”) as independent registered public accounting firm of the Company effective December 2, 2025. This change was not a result of any disagreement between the Company and Deloitte.

    The audit reports of Deloitte on the Company’s financial statements for the years ended June 30, 2025 and 2024 did not contain an adverse opinion or disclaimer of opinion, and such reports were not qualified or modified as to uncertainty, audit scope, or accounting principle.

    During the fiscal years ended June 30, 2025 and 2024, and the subsequent interim period through September 30, 2025, there were: (i) no “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Deloitte on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Deloitte’s satisfaction, would have caused Deloitte to make reference to them in its reports; and (ii) no “reportable events” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

    The Company provided Deloitte with a copy of the disclosures the Company is making in this Current Report on Form 8-K and requested that Deloitte furnish a letter to the Company addressed to the U.S. Securities and Exchange Commission ("SEC") stating whether it agrees with the statements made herein. A copy of Deloitte’s letter, stating its agreement with such statements, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

    During the fiscal years ended June 30, 2025 and 2024, and the interim period through September 30, 2025, the Company did not consult with CBIZ CPAs regarding: (i) the application of accounting principles to a specified transaction, either proposed or completed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ CPAs concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

     

    Item 9.01 Financial Statements and Exhibits.

    Exhibit Number

    Exhibit Title

    16.1

    Letter from Deloitte

    104

    Cover Page Interactive Data File (formatted as inline XBRL)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    LITE STRATEGY, INC.

     

     

     

     

    Date:

    December 5, 2025

    By:

    /s/ Justin J. File

     

     

     

    Justin J. File
    Chief Executive Officer, Chief Financial Officer and Secretary

     


    Get the next $LITS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LITS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LITS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by CEO, CFO and Secretary File Justin J.

    4/A - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 5:29:57 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Glover Nicholas

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/19/25 1:41:38 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

    SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company's digital asset treasury strategy as well as its pharmaceutical operations. "Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus," Board Member Charlie Lee said. "We recently celebrated Litecoin's 14th anniversary and its unblemished track record of reliability and uptime. LITS provides inv

    11/17/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

    SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS") today announced its Board of Directors has authorized a program to repurchase shares of the Company's Common Stock, par value $0.00000002 per share (the "Common Stock"), up to an aggregate amount of $25 million. The share repurchase program is effective immediately, and provides for shares to be repurchased in the open market or through negotiated transactions. "Our top priority is to enhance stockholder value," said Board Member Joshua Riezman, U.S. Chief Strategy Officer at GSR, which is advising the Company on its treasury strategy, "and the share repurchase program is one of th

    10/29/25 9:00:00 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026

    SAN DIEGO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ:LITS) ("Lite Strategy" or "LITS"), the first U.S.-listed public company to adopt Litecoin as its primary reserve asset, joins the digital asset community in celebrating the 14th anniversary of Litecoin (LTC), and its role as the second-longest-running blockchain in crypto and a model of network resilience. "As we celebrate this historic time, we see that Litecoin's 14-year track record of reliability and uptime continues to attract more institutional interest. As institutions look for digital assets with proven durability and sound hard-money principles, Litecoin stands out as a strong choice for both treasury divers

    10/16/25 4:06:43 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Flynn James P bought $22,777 worth of shares (12,100 units at $1.88), increasing direct ownership by 68% to 30,000 units (SEC Form 4)

    4 - Lite Strategy, Inc. (0001262104) (Issuer)

    11/20/25 4:00:03 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LITS
    SEC Filings

    View All

    Lite Strategy Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Lite Strategy, Inc. (0001262104) (Filer)

    12/5/25 4:00:24 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lite Strategy Inc.

    EFFECT - Lite Strategy, Inc. (0001262104) (Filer)

    11/26/25 12:15:27 AM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 8-K/A filed by Lite Strategy Inc.

    8-K/A - Lite Strategy, Inc. (0001262104) (Filer)

    11/20/25 5:29:48 PM ET
    $LITS
    Biotechnology: Pharmaceutical Preparations
    Health Care